ELIZABETH PETITT: Open Payments
NPI 1750941910 · HALFMOON, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,636 in 79 payments from 24 companies in 2025. Trend: 2023 $2,540 · 2024 $1,838 · 2025 $2,636
Food & beverage: $2,636
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 17 | $440 |
| Lilly USA, LLC | 9 | $285 |
| AstraZeneca Pharmaceuticals LP | 8 | $284 |
| Novo Nordisk Inc | 7 | $240 |
| Janssen Pharmaceuticals, Inc | 4 | $204 |
| Abbott Laboratories | 4 | $181 |
| GlaxoSmithKline, LLC. | 6 | $131 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $124 |
| Neurelis, Inc. | 1 | $121 |
| Boston Scientific Corporation | 1 | $112 |
Products named: ZEPBOUND, SPRAVATO, Ozempic, VRAYLAR, FREESTYLE LIBRE 3, QULIPTA, AIRSUPRA, BREZTRI.
Industry payments across NY — which companies pay providers there.
